AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

by Barry101 | Nov 2, 2022 | Press Release, Uncategorized

Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system Ampligen has demonstrated positive results for the treatment...

Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid

by Barry101 | Oct 31, 2022 | Press Release, Uncategorized

Court Denies Jonathan Jorgl’s Request for Preliminary Injunction; Finds that Jorgl Failed to Show Director Nomination Notice Complied with AIM’s Bylaws and that Evidence Suggests Notice was Misleading Activist Group Cannot Nominate Directors to AIM’s...

AIM ImmunoTech Board Issues Letter to Shareholders

by Barry101 | Oct 26, 2022 | Press Release

Corrects the Record Regarding Activist Group’s False and Misleading Statements Highlights Evidence of Group’s Scheme to Have Jorgl Serve as the “Face of the Activist” to Help Them “Get Control” Without Paying a Premium to All...

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

by Barry101 | Oct 12, 2022 | Press Release, Uncategorized

Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of...

AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

by Barry101 | Sep 21, 2022 | Press Release, Uncategorized

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ETOCALA,...